Filing Details

Accession Number:
0000914475-14-000081
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-12-12 17:48:01
Reporting Period:
2014-12-10
Filing Date:
2014-12-12
Accepted Time:
2014-12-12 17:48:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
914475 Neurocrine Biosciences Inc NBIX Biological Products, (No Disgnostic Substances) (2836) 330525145
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1376043 P Timothy Coughlin Neurocrine Biosciences, Inc.
12780 El Camino Real
San Diego CA 92130
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-12-10 10,000 $2.59 107,874 No 4 M Direct
Common Stock Disposition 2014-12-10 10,000 $21.00 97,874 No 4 S Direct
Common Stock Acquisiton 2014-12-10 10,000 $5.12 107,874 No 4 M Direct
Common Stock Disposition 2014-12-10 10,000 $21.95 97,874 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Incentive Stock Option Acquisiton 2014-12-10 10,000 $5.12 10,000 $5.12
Common Stock Nonstatutory Stock Option Acquisiton 2014-12-10 10,000 $2.59 10,000 $2.59
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
140,000 2008-02-27 2015-02-27 No 4 M Direct
140,000 2010-06-11 2017-05-11 No 4 M Direct
Footnotes
  1. Exercise or conversion of derivative security exempted pursuant to Rule 10b-3.
  2. The dispositions reported in this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.